EUIPOSchützen Sie diese Marke vor Nachahmern!
Mit unserer Markenüberwachung werden Sie automatisch per E-Mail über Nachahmer und Trittbrettfahrer benachrichtigt.
Die Unionsmarke LEXEO THERAPEUTICS wurde als Wortmarke am 04.04.2024 beim Amt der Europäischen Union für Geistiges Eigentum angemeldet. Der aktuelle Status der Marke ist "Anmeldung wird geprüft".
| Markenform | Wortmarke |
| Aktenzeichen | 019009041 |
| Anmeldedatum | 04. April 2024 |
Markeninhaber
345 Park Avenue South, Sixth Floor
10010 New York, NY
US
10010 New York, NY
US
Markenvertreter
Harrlachweg 4
68163 Mannheim
DE
Waren und Dienstleistungen
5
Pharmaceutical preparations for the treatment of cardiovascular diseases, disorders, and defects; Pharmaceutical preparations for the treatment of Friedreich's Ataxia; Pharmaceutical preparations for the treatment of arrhythmogenic cardiomyopathy; Pharmaceutical preparations for the treatment of hypertrophic cardiomyopathy; Pharmaceutical preparations for the treatment of central nervous system diseases, disorders, and defects; Pharmaceutical preparations for the treatment of Alzheimer's disease; Pharmaceutical preparations for the treatment of Batten disease; Pharmaceutical preparations for the treatment of genetic diseases, disorders, and defects; Pharmaceutical preparations for the treatment of monogenic diseases, disorders, and defects; Gene therapy for the treatment of diseases, disorders, and defects; Therapeutic agents for delivery of genetically engineered viruses to patients for targeting underlying causes of diseases, disorders, and defects; Therapeutic agents for delivery of genetically engineered viruses to patients for treatment of diseases, disorders, and defects; Pharmaceutical preparations for the detection or diagnosis of cardiovascular diseases, disorders, and defects; Pharmaceutical preparations for the detection or diagnosis of Friedreich's Ataxia; Pharmaceutical preparations for the detection or diagnosis of arrhythmogenic cardiomyopathy; Pharmaceutical preparations for the detection or diagnosis of hypertrophic cardiomyopathy; Pharmaceutical preparations for the detection or diagnosis of central nervous system diseases, disorders, and defects; Pharmaceutical preparations for the detection or diagnosis of Alzheimer's disease; Pharmaceutical preparations for the detection or diagnosis of Batten disease; Pharmaceutical preparations for the detection or diagnosis of genetic diseases, disorders, and defects; Pharmaceutical preparations for the detection or diagnosis of monogenic diseases, disorders, and defects; Gene therapy for the detection or diagnosis of diseases, disorders, and defects; Therapeutic agents for delivery of genetically engineered viruses to patients for detection or diagnosis of underlying causes of diseases, disorders, and defects; Therapeutic agents for delivery of genetically engineered viruses to patients for detection or diagnosis of diseases, disorders, and defects
Die Bezeichnungen wurden automatisch übersetzt. Übersetzung anzeigen
ID: 11019009041